Key points are not available for this paper at this time.
Several lines of evidence indicate that cholecystokinin (CCK) antagonists potentiate analgesia induced by exogenous opioids. Similarly, CCK antagonists enhance analgesia induced by procedures that activate endogenous opioid systems. However, because there are substantial species differences in receptor specificity and distribution, the role of CCK type A and type B receptors has yet to be clearly established.
Fabrizio Benedetti (Mon,) studied this question.